NCT07182422View on ClinicalTrials.gov

AST-120 (Kremezin®) for the Renal Protection and Attenuation of Decline in Acute Kidney Disease

PHASE4RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

September 15, 2025

Primary Completion Date

February 11, 2027

Study Completion Date

March 13, 2027

Conditions
Acute Kidney DiseaseAcute Kidney Injury (AKI)
Interventions
DRUG

AST-120 (Kremezin®)

AST-120 (Kremezin®) Dosage: 6 g/day (2 g TID, oral) Duration: 14 days Background treatment: Standard post-AKD care

Trial Locations (1)

333

RECRUITING

Chang Gung Memorial Hospital, Taoyuan, Taiwan, Taoyuan District

All Listed Sponsors
collaborator

Conmed Pharmaceutical & Bio-Medical Corporation

INDUSTRY

lead

Chang Gung Memorial Hospital

OTHER

NCT07182422 - AST-120 (Kremezin®) for the Renal Protection and Attenuation of Decline in Acute Kidney Disease | Biotech Hunter | Biotech Hunter